Researchers have been looking at, and I've reported on their research, regarding HDAC inhibitors for some time. Initially, they were considered as something that could be added to targeted therapy in order to prevent, delay, or overcome resistance to BRAF inhibitors. It has also been postulated that combining HDAC inhibitors with immunotherapy could increase the effectiveness of that therapy by making melanoma cells more sensitive to it. Entinostat and Ricolinostat are two such HDAC inhibitors.
Now there's this:
Step by step! Hopefully these inhibitors will benefit real live melanoma ratties very soon!!! - c